A Study to Assess the Adverse Events and How Subcutaneous (SC) Injections and Intravenous (IV) Infusions of ABBV-142 Move Through the Body of Healthy Adult Participants

Launched by ABBVIE · Jan 9, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called ABBV-142 to understand how it moves through the body when given as a shot under the skin (subcutaneous) or through an IV (intravenous infusion). The researchers want to find out if the treatment is safe, how well it is tolerated, and whether it triggers any immune response in healthy adult volunteers. The goal is to ensure that the doses given in the study are safe for people.

To participate, volunteers need to be generally healthy and fall within a specific age range. For one part of the study, they are looking for individuals who are first- or second-generation Han Chinese or Japanese, living outside of their home countries, and who maintain a typical lifestyle and diet from their culture. Participants can expect to undergo tests and receive the treatment while being closely monitored for any side effects. It's important to note that individuals with certain health issues, recent illnesses, or those who use tobacco or have a history of drug or alcohol abuse will not be eligible for this study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• All Parts:
• • • Volunteers in general good health.
• Part 3, ONLY:
• HAN CHINESE Participants:
• • Participant must be first- or second-generation Han Chinese of full Chinese parentage (both parents of Han Chinese descent), residing outside of China. Participants must be in general good health.
• • First-generation participants will have been born in China to two parents and four grandparents, who were also born in China, and are of full Chinese descent.
• • Second-generation participants born outside of China must have two parents and four grandparents born in China and are of full Chinese descent.
• • OR
• JAPANESE Participants:
• • Participant must be first- or second-generation Japanese parentage (both parents of Japanese descent), residing outside of Japan. Participants must be in general good health.
• • First-generation participants will have been born in Japan to two parents and four grandparents born in Japan and are of full Japanese descent.
• • Second-generation participants born outside of Japan must have two parents and four grandparents born in Japan and are of full Japanese descent.
• Exclusion Criteria:
• • History of any clinically significant illness/infection/major febrile illness, hospitalization, or any surgical procedure within 30 days prior to the first dose of study drug.
• • Use of tobacco or nicotine-containing products within 180 days prior to the first dose of study drug.
• • History of clinically significant (per investigator's judgment) drug or alcohol abuse within the last 6 months.